# A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma

> **NCT06392477** · PHASE1 · RECRUITING · sponsor: **Sanofi** · enrollment: 96 (estimated)

## Conditions studied

- B-cell Non Hodgkin Lymphoma

## Interventions

- **DRUG:** SAR448501

## Key facts

- **NCT ID:** NCT06392477
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-08
- **Primary completion:** 2028-01-21
- **Final completion:** 2028-02-11
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06392477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06392477, "A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06392477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*